TY  - JOUR
AU  - Ćujić, Nada
AU  - Ibrić, Svetlana
AU  - Bigović, Dubravka
AU  - Noveski, Nebojša
AU  - Šavikin, Katarina
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2482
AB  - Nowdays, the use of products based on medicinal herbs (phytopreparates) are in scientific focus, both in prevention or in treatment of various diseases. Herbal products have been recognized as an excellent source of bioactive compounds which have positive effects on human health. Beside teas, as standard herbal products, phytopreparations are much more represented as final pharmaceutical form on the market today. Phytopreparations must satisfy standard quality, which means that they must be physically, chemically and microbiological stable and have a high degree of purity. In order to determine the stability, storage conditions, shelf-life of the products, stability tests are conducted, which involving tests of environmental factors influence: temperature, relative humidity, light. Stability tests are performed at different stages of development and production. In accordance with the EMEA (European Agency for Drugs and Medical Devices) for a variety of herbal preparations different specific stability tests are conducted.
AB  - Danas, sve je veći akcenat na upotrebi preparata na bazi lekovitog bilja (fitopreparata), kako u prevenciji tako i u lečenju različitih oboljenja. Biljni preparati su prepoznati kao odličan izvor bioaktivnih komponenti, koji imaju pozitivne efekte na zdravlje ljudi. Pored čajeva, kao standardnih biljnih proizvoda, danas su na tržištu mnogo više zastupljeni fitopreparati kao finalne farmaceutske forme. Fitopreparati moraju biti standardnog kvaliteta, što podrazumeva da moraju biti fizički, hemijski i mikrobilološki stabilni, da su standardizovanog sastava i da su visokog stepena čistoće. U cilju utvrđivanja koliko je jedan proizvod stabilan, definisanja uslova čuvanja, određivanja roka trajanja, sprovode se ispitivanja stabilnosti, koja podrazumevaju ispitivanja uticaja faktora okoline: temperature, relativne vlažnosti vazduha, svetlosti na promenu kvaliteta gotovog proizvoda. Ispitivanja stabilnosti se izvode u različitim fazama razvoja i proizvodnje. U skladu sa zahtevima EMEA (Evropska agencija za lekove i medicinska sredstva) za različite biljne preparate postavljaju se različiti specifični testovi stabilnosti.
PB  - Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd
T2  - Lekovite sirovine
T1  - Stability testing of herbal medicines
T1  - Ispitivanje stabilnosti biljnih preparata
IS  - 35
SP  - 53
EP  - 60
DO  - 10.5937/leksir1535053C
ER  - 

@article{
author = "Ćujić, Nada and Ibrić, Svetlana and Bigović, Dubravka and Noveski, Nebojša and Šavikin, Katarina",
year = "2015",
abstract = "Nowdays, the use of products based on medicinal herbs (phytopreparates) are in scientific focus, both in prevention or in treatment of various diseases. Herbal products have been recognized as an excellent source of bioactive compounds which have positive effects on human health. Beside teas, as standard herbal products, phytopreparations are much more represented as final pharmaceutical form on the market today. Phytopreparations must satisfy standard quality, which means that they must be physically, chemically and microbiological stable and have a high degree of purity. In order to determine the stability, storage conditions, shelf-life of the products, stability tests are conducted, which involving tests of environmental factors influence: temperature, relative humidity, light. Stability tests are performed at different stages of development and production. In accordance with the EMEA (European Agency for Drugs and Medical Devices) for a variety of herbal preparations different specific stability tests are conducted., Danas, sve je veći akcenat na upotrebi preparata na bazi lekovitog bilja (fitopreparata), kako u prevenciji tako i u lečenju različitih oboljenja. Biljni preparati su prepoznati kao odličan izvor bioaktivnih komponenti, koji imaju pozitivne efekte na zdravlje ljudi. Pored čajeva, kao standardnih biljnih proizvoda, danas su na tržištu mnogo više zastupljeni fitopreparati kao finalne farmaceutske forme. Fitopreparati moraju biti standardnog kvaliteta, što podrazumeva da moraju biti fizički, hemijski i mikrobilološki stabilni, da su standardizovanog sastava i da su visokog stepena čistoće. U cilju utvrđivanja koliko je jedan proizvod stabilan, definisanja uslova čuvanja, određivanja roka trajanja, sprovode se ispitivanja stabilnosti, koja podrazumevaju ispitivanja uticaja faktora okoline: temperature, relativne vlažnosti vazduha, svetlosti na promenu kvaliteta gotovog proizvoda. Ispitivanja stabilnosti se izvode u različitim fazama razvoja i proizvodnje. U skladu sa zahtevima EMEA (Evropska agencija za lekove i medicinska sredstva) za različite biljne preparate postavljaju se različiti specifični testovi stabilnosti.",
publisher = "Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd",
journal = "Lekovite sirovine",
title = "Stability testing of herbal medicines, Ispitivanje stabilnosti biljnih preparata",
number = "35",
pages = "53-60",
doi = "10.5937/leksir1535053C"
}

Ćujić, N., Ibrić, S., Bigović, D., Noveski, N.,& Šavikin, K.. (2015). Stability testing of herbal medicines. in Lekovite sirovine
Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd.(35), 53-60.
https://doi.org/10.5937/leksir1535053C

Ćujić N, Ibrić S, Bigović D, Noveski N, Šavikin K. Stability testing of herbal medicines. in Lekovite sirovine. 2015;(35):53-60.
doi:10.5937/leksir1535053C .

Ćujić, Nada, Ibrić, Svetlana, Bigović, Dubravka, Noveski, Nebojša, Šavikin, Katarina, "Stability testing of herbal medicines" in Lekovite sirovine, no. 35 (2015):53-60,
https://doi.org/10.5937/leksir1535053C . .

TY  - JOUR
AU  - Ćujić, Nada
AU  - Ibrić, Svetlana
AU  - Bigović, Dubravka
AU  - Noveski, Nebojša
AU  - Šavikin, Katarina
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2481
AB  - In recent years, drug delivery systems are especially interesting because they allow therapeutic efficiency and reduce side effects. Conjugates of hyaluronic acid and chemotherapeutic agents, especially taxol, have been recognized as excellent solution for many therapeutic indications. The aim of conjugation of taxol with hyaluronic acid was the toxicity reduction on healthy cells and increase of selectivity on tumor cells. Hyaluronic acid could be used in various pharmaceutical preparations, also in parenteral, because of its biocompatibility and biodegradability. Hyaluronic acid as a carrier belongs to in situ gelling systems, which is passing a phase transition in response to external conditions such as temperature, different pH value or the presence of ions, enabling prolonged effect of the drug substances. Many tumor cells have a large number of receptors for hyaluronic acid, which has a great affinity for the tumor cells. The incorporation of taxol in gelling system of hyaluronic acid provides sustained drug release, increased anticancer activity, reduced damage of healthy cells and increased selectivity on cancer cells.
AB  - Preparati sa produženim oslobađanjem su poslednjih godina posebno aktuelni jer omogućavaju veću terapijsku efikasnost, smanjuju pojavu neželjenih efekata i omogućavaju ciljano delovanje. Posebno su poslednjih godina interesantni konjugati hijaluronske kiseline i citostatika, a jedan od njih je i taksol, koji pored mnogobrojnih terapijskih indikacija ispoljava i niz neželjenih efekata. Cilj konjugovanja taksola sa hijaluronskom kiselinom je smanjenje toksičnosti na zdravim i povećanje selektivnosti na tumorskim ćelijama. Hijaluronska kiselina se može primenjivati u različitim farmaceutskim preparatima, pa i u parenteralnim, jer ima niz prednosti kao što su biokompatibilnost i biodegradibilnost. Spada u in situ gelirajuće sisteme koji se podvrgavaju faznom prelazu u odgovoru na spoljne stimulanse kao što su temperatura, pH ili prisustvo jona, čime se omogućava produženo dejstvo lekovite supstance. Mnoge tumorske ćelije pokazuju ekspresiju velikog broja receptora za hijaluronsku kiselinu, pa ona ima veliki afinitet za tumorske ćelije. Inkorporiranjem taksola u gelirajući sistem sa hijaluronskom kiselinom omogućava se postepeno oslobađanje leka, povećanje antikancerskog delovanja, smanjuje se oštećenje zdravih ćelija i povećava selektivnost leka.
PB  - Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd
T2  - Lekovite sirovine
T1  - Pharamaceutical hyaluronic acid based carriers for parenteral use, particularly conjugates with taxol: A review
T1  - Nosači/preparati na bazi hijaluronske kiseline za parenteralnu primenu sa posebnim osvrtom na konjugaciju sa taksolom
IS  - 35
SP  - 75
EP  - 87
DO  - 10.5937/leksir1535075C
ER  - 

@article{
author = "Ćujić, Nada and Ibrić, Svetlana and Bigović, Dubravka and Noveski, Nebojša and Šavikin, Katarina",
year = "2015",
abstract = "In recent years, drug delivery systems are especially interesting because they allow therapeutic efficiency and reduce side effects. Conjugates of hyaluronic acid and chemotherapeutic agents, especially taxol, have been recognized as excellent solution for many therapeutic indications. The aim of conjugation of taxol with hyaluronic acid was the toxicity reduction on healthy cells and increase of selectivity on tumor cells. Hyaluronic acid could be used in various pharmaceutical preparations, also in parenteral, because of its biocompatibility and biodegradability. Hyaluronic acid as a carrier belongs to in situ gelling systems, which is passing a phase transition in response to external conditions such as temperature, different pH value or the presence of ions, enabling prolonged effect of the drug substances. Many tumor cells have a large number of receptors for hyaluronic acid, which has a great affinity for the tumor cells. The incorporation of taxol in gelling system of hyaluronic acid provides sustained drug release, increased anticancer activity, reduced damage of healthy cells and increased selectivity on cancer cells., Preparati sa produženim oslobađanjem su poslednjih godina posebno aktuelni jer omogućavaju veću terapijsku efikasnost, smanjuju pojavu neželjenih efekata i omogućavaju ciljano delovanje. Posebno su poslednjih godina interesantni konjugati hijaluronske kiseline i citostatika, a jedan od njih je i taksol, koji pored mnogobrojnih terapijskih indikacija ispoljava i niz neželjenih efekata. Cilj konjugovanja taksola sa hijaluronskom kiselinom je smanjenje toksičnosti na zdravim i povećanje selektivnosti na tumorskim ćelijama. Hijaluronska kiselina se može primenjivati u različitim farmaceutskim preparatima, pa i u parenteralnim, jer ima niz prednosti kao što su biokompatibilnost i biodegradibilnost. Spada u in situ gelirajuće sisteme koji se podvrgavaju faznom prelazu u odgovoru na spoljne stimulanse kao što su temperatura, pH ili prisustvo jona, čime se omogućava produženo dejstvo lekovite supstance. Mnoge tumorske ćelije pokazuju ekspresiju velikog broja receptora za hijaluronsku kiselinu, pa ona ima veliki afinitet za tumorske ćelije. Inkorporiranjem taksola u gelirajući sistem sa hijaluronskom kiselinom omogućava se postepeno oslobađanje leka, povećanje antikancerskog delovanja, smanjuje se oštećenje zdravih ćelija i povećava selektivnost leka.",
publisher = "Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd",
journal = "Lekovite sirovine",
title = "Pharamaceutical hyaluronic acid based carriers for parenteral use, particularly conjugates with taxol: A review, Nosači/preparati na bazi hijaluronske kiseline za parenteralnu primenu sa posebnim osvrtom na konjugaciju sa taksolom",
number = "35",
pages = "75-87",
doi = "10.5937/leksir1535075C"
}

Ćujić, N., Ibrić, S., Bigović, D., Noveski, N.,& Šavikin, K.. (2015). Pharamaceutical hyaluronic acid based carriers for parenteral use, particularly conjugates with taxol: A review. in Lekovite sirovine
Institut za proučavanje lekovitog bilja Dr Josif Pančić, Beograd.(35), 75-87.
https://doi.org/10.5937/leksir1535075C

Ćujić N, Ibrić S, Bigović D, Noveski N, Šavikin K. Pharamaceutical hyaluronic acid based carriers for parenteral use, particularly conjugates with taxol: A review. in Lekovite sirovine. 2015;(35):75-87.
doi:10.5937/leksir1535075C .

Ćujić, Nada, Ibrić, Svetlana, Bigović, Dubravka, Noveski, Nebojša, Šavikin, Katarina, "Pharamaceutical hyaluronic acid based carriers for parenteral use, particularly conjugates with taxol: A review" in Lekovite sirovine, no. 35 (2015):75-87,
https://doi.org/10.5937/leksir1535075C . .